Summary of AMP Trades in December


In December, AMP started new positions in Regulus Therapeutics, Protagonist Therapeutics, SC Pharmaceuticals. AMP also added to it's Nabriva Therapeutics and Cidara Therapeutics positions. Further, AMP trimmed more of its Nektar Therapeutics position taking a profit of more than $30K in hypothetical gains (NKTR was up 280% at the time of sale).


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon